Hims & Hers continues to deliver strong subscriber and revenue growth, with Q1 2025 revenue up 111% YoY. Check out why I ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten this week with a federal deadline to ...

Novo Nordisk, the global pharmaceutical leader headquartered in Denmark, has launched a major initiative to combat Thailand's growing obesity crisis, where more than 40% of the population is now ...

In the near term, commercial efforts might raise the chances that new patients are prescribed Novo Nordisk’s drug, assuming ...

"I'm not going to second-guess myself."Wegovy belongs to a pricey class of drugs called GLP-1s (short for glucagon-like ...

As its obesity medication Wegovy loses a sizable portion of the market to Eli Lilly and Company (NYSE:LLY)’s competing ...

More than a dozen lawsuits have been filed on behalf of weight-loss drug users who claim that popular weight-loss medications ...

Novo Nordisk ( NVO 1.82%) stock jumped 3% through 10:55 a.m. Tuesday on some potentially positive news in the GLP-1 weight ...

Online weight-loss company Noom has begun offering smaller doses of compounded versions of Novo Nordisk's Wegovy as the U.S.